Platform of Polymeric Conjugates
for Selective Intracorporeal Removal
of Specific Harmful Antibodies
Discovery
PoC
Pre-clinical
Phase I
Phase II
RA0127
70%Antibody-dependent enhancement (ADE) of bacterial infections occurs when blocking antibodies facilitate the infectivity of pathogens. Natural antibodies against Galα1-3Galβ1-4GlcNAcβ (αGal) epitope act as blocking antibodies against Gram-negative bacteria. This phenomenon contributes to the global and increasing the augment of antimicrobial resistance (AMR).The Intensive Care Unit (ICU) is the worst scenario for AMR. Patients admitted to ICUs are at high risk of acquiring infections, mainly by gram-negative bacteria, because of their underlying illness and constant exposure to invasive practices. RA0127 removes anti-αGal antibodies and is developed to protect ICU patients from Gram-negative bacterial infections.
RA0118
50%Most of autoimmune disorders are characterized by the production of antibodies directed to self-antigens.
For instance, people exposed to hard tick bites are sensitized to αGal, producing elevated levels of anti-αGal IgE that cause allergic reactions to red meat and monoclonal antibodies used to treat different diseases. In addition, anti-αGal antibodies appear to have a significant role in developing autoimmune diseases such as Graves-Basedow.
RA0118 is a family of polymeric conjugates that selectively removes some types anti-αGal immunoglobulins for treating allergic and autoimmune disorders.
RA02AB
35%The AB0 blood group antigens are carbohydrate epitopes located on the surfaces of cells. Anti-A and anti-B antibodies bind to the antigens leading to complement fixation and causing intravascular hemolysis of red blood cells in blood transfusion and hyperacute rejection of vascularized organs in organ transplantation. RA02A/RA02B are new carbohydrate derivatives of blood group A and B antigens that bind anti-A and anti-B antibodies, avoiding disorders related to AB0 blood group incompatibility.
RAAV03
45%Gene therapy replaces a disease-causing gene with a healthy copy of the gene by using viral vectors like adeno-associated virus (AAV). Human antibodies usually neutralize these viral vectors because of pre-existing immunity against AAV. Anti-AAV neutralizing antibodies (NAbs) profoundly impact the efficacy of gene transfer. Therefore, one crucial goal of gene therapy is reducing the levels of NAbs against AAV. RAAV03 aims to avoid the human immune response mediated by antibodies against the AAV viral vectors.